Vonliv 10 10 mg Tablet

Vonliv 10 10 mg tablet is manufactured by Opsonin Pharma Limited and contains Vonoprazan, a potassium-competitive acid blocker (P-CAB) — a newer class of acid-reducing medicine than the familiar proton pump inhibitors (PPIs). Vonliv 10 is used for acid reflux, erosive oesophagitis, peptic ulcers and as part of H. pylori eradication therapy.

Vonoprazan works by blocking the potassium-binding site of the stomach's proton pumps in a reversible, competitive way. Unlike PPIs, it does not need acid activation or a pre-meal timing, so it starts suppressing acid rapidly — often from the first dose — and maintains strong, stable acid control throughout the day and night.

Vonoprazan is used for:

• Erosive oesophagitis (reflux oesophagitis) — healing and maintenance of healing
• Gastro-oesophageal reflux disease (GERD) — relief of heartburn and regurgitation
• Gastric and duodenal ulcers — including ulcers associated with low-dose aspirin or NSAIDs in some countries
• Helicobacter pylori eradication — combined with antibiotics, where its strong acid suppression improves eradication rates

Because it is a newer medicine, indications may vary between countries; your registered doctor will decide whether Vonliv 10 suits your condition.

Commonly used adult doses of Vonliv 10:

• Erosive oesophagitis: 20 mg once daily for up to 4-8 weeks; maintenance often 10-20 mg once daily
• Gastric/duodenal ulcer: 20 mg once daily, typically 6-8 weeks as advised
• H. pylori eradication: 20 mg twice daily with antibiotics for 7-14 days

Vonliv 10 can be taken with or without food, at roughly the same time each day. Swallow the tablet whole with water. The precise dose and duration must be decided by a registered doctor. Use in children is limited and should only follow a specialist's weight-based prescription.

Vonoprazan is generally well tolerated. Possible side effects:

• Common: constipation, diarrhoea, nausea, abdominal discomfort, headache
• Less common: rash, itching, raised liver enzymes, dizziness
• Potential with prolonged use: as with other strong acid suppressants — gut infections, low magnesium and reduced vitamin B12 absorption; long-term data are still accumulating since this is a newer class

Contact a doctor promptly if you develop yellowing of the eyes or skin, severe rash, persistent diarrhoea, or any allergic symptoms such as facial swelling or breathing difficulty.

Precautions for Vonoprazan:

• Tell your doctor about liver problems — dose adjustment or extra monitoring may be needed
• Before starting, alarm symptoms (weight loss, vomiting blood, black stools, difficulty swallowing) should be evaluated, as strong acid suppression can mask gastric malignancy
• Use the shortest effective duration; long-term need should be reviewed periodically
• Strong acid suppression may increase susceptibility to certain gut infections such as Salmonella and C. difficile
• As a newer medicine, report any unexpected reactions to your doctor

Vonoprazan interactions to know about:

• Acid-dependent drugs: markedly reduced absorption of atazanavir, rilpivirine, itraconazole, ketoconazole and some iron preparations
• CYP3A4 inhibitors/inducers: drugs such as clarithromycin may raise vonoprazan levels, while rifampicin-type inducers may lower them
• Clopidogrel: interaction appears less significant than with omeprazole, but inform your doctor
• Digoxin: levels may rise with reduced gastric acidity; monitoring may be advised

Provide your doctor and pharmacist with a full list of your current medicines before starting Vonliv 10.

Vonoprazan must not be used when:

• There is known hypersensitivity to vonoprazan or any component of the tablet
• The patient is taking atazanavir or rilpivirine-containing medicines, whose absorption depends on stomach acid

It should be used cautiously, only under medical supervision, in patients with significant hepatic impairment and in the elderly. As experience in pregnancy, breastfeeding and children is limited, use in these groups requires a doctor's careful benefit-risk assessment.

Pregnancy: Human data on vonoprazan in pregnancy are very limited because it is a newer medicine. It should be avoided unless a doctor decides the expected benefit clearly outweighs potential risk; better-studied alternatives are usually preferred during pregnancy.

Lactation: Vonoprazan passes into milk in animal studies, and human data are lacking. Breastfeeding mothers should generally avoid it, or a doctor may advise temporarily stopping breastfeeding if treatment is essential. Always consult your doctor before using Vonliv 10 while pregnant or nursing.

Store below 30°C in a dry place, away from direct sunlight and moisture. Keep the tablet in its original blister pack until the moment of use. Keep out of the reach and sight of children. Do not use beyond the expiry date printed on the packaging, and avoid storing in hot or humid locations such as kitchens and bathrooms.